Combination therapy for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a combination of two drugs (trastuzumab rezetecan and bevacizumab) for women with ovarian cancer that has returned after initial treatment. The goal is to see if this combination helps control the cancer longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 18 and 75 years old.
- You have epithelial ovarian, fallopian tube, or primary peritoneal cancer (not mucinous).
- You have had 1 or 2 prior chemotherapy treatments and you have also taken a PARP inhibitor.
- Your cancer came back between 6 and 12 months after your last platinum chemo.
- Your tumor tests positive for HER2 (IHC 1+, 2+, or 3+).
- You are able to do daily activities with little or no help (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a targeted therapy (trastuzumab) to the usual maintenance drug (bevacizumab) helps keep ovarian cancer from coming back after first-line chemo. It is for people with certain genetic markers and who have completed initial treatment without the cancer growing.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.